Alvotech has announced its financial results for the first nine months of 2026, revealing a significant decline in total revenue compared to the previous year. The company reported adjusted total revenue of $323.4 million, down from $420.0 million in the same period last year. This decline underscores the challenges facing the biosimilar market, as Alvotech navigates a competitive landscape.
Alvotech, a biotechnology company specializing in the development and manufacture of biosimilar medicines, is listed on the Nasdaq under the tickers ALVO and ALVOW. The company is classified under the SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances). Alvotech has been actively involved in the biosimilar sector, aiming to provide high-quality, cost-effective products to patients worldwide.
The recent filing indicates that Alvotech's gross margin for the nine months ending September 30, 2026, was 54%, down from 59% in the same period last year. The adjusted EBITDA for the same period was $78.3 million, an increase from $68.0 million year-over-year. However, the cash balance at the end of September 2026 was reported at $61.5 million, a decrease from $172.4 million at the end of 2025.
In the press release accompanying the filing, Alvotech highlighted several recent business developments. The FDA accepted the company's Biologics License Application (BLA) for AVT80, a proposed biosimilar to Entyvio, and Alvotech submitted the first known regulatory submission worldwide for a proposed biosimilar to Eylea HD. Additionally, the company signed agreements with Lotus Pharmaceuticals for commercialization rights in the U.S. and selected Asian markets.
Lisa Graver, Alvotech's CEO, commented on the company's performance, stating, "Our commercial performance strengthened in the third quarter, with product and service revenue reaching $58 million, up 6% sequentially and 78% year over year." Graver emphasized the importance of recent FDA approvals for Simlandi, which will enhance the company's manufacturing capacity and operational flexibility.
Looking ahead, Alvotech has maintained its full-year guidance for total revenue between $650 million and $700 million, with EBITDA expected to be between $180 million and $220 million. The company anticipates performance toward the lower end of this range as it ramps up production and commercial supply following a manufacturing improvement program completed earlier in the year.
In summary, Alvotech's financial results reflect the ongoing challenges in the biosimilar market, but the company is taking steps to strengthen its position through strategic partnerships and expansion of its manufacturing capabilities. The filing, with accession number 0001171843-26-007377, provides a detailed overview of Alvotech's current financial standing and future outlook.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










